BSE filing, NSE: INDOCO. Summary written from the filing by ALFA Finder's alert engine.
Indoco Remedies Ltd: key numbers
- Share price
- ₹213.75
- Market cap
- ₹1,973 Cr
- Revenue (annual)
- ₹1,845 Cr
- Net profit (annual)
- ₹-95.14 Cr
- P/E (TTM)
- 61.8×Sector 46.1×
- Promoter holding
- 58.92%+0.06% QoQ
- FII holding
- 1.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Indoco Remedies Ltd
All →Indoco Remedies Earnings Call Transcript: Key Takeaways
Indoco Remedies hit record quarterly revenue exceeding ₹500 Cr, but faced margin compression from elevated geopolitical freight and material costs.
- Call
- Guides 10% growth
Indoco Remedies Business Update
Indoco's CRO AnaCipher received ANVISA Brazil approval for clinical and bioanalytical facilities. This expands its regulatory footprint to conduct bioequivalence studies in Brazil and Latin America.
Indoco Remedies Q2 FY27 Results: Turns Profitable, Net Profit ₹19.5 Cr
Indoco Remedies Ltd reported revenue from operations of ₹506.9 Cr (+7.4% YoY) and net profit of ₹19.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹19.5 Cr
Indoco Remedies Employee Stock Options
Indoco Remedies allotted 14,850 ESOP shares to its Employees Welfare Trust under the 2022 ESOP plan. The allotment is at face value with no transaction price.
Indoco Remedies Other Announcement
Indoco Remedies Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in accordance with SEBI Regulation 31(1)(b).
Indoco Remedies Merger & Restructuring Worth ₹0.01 Cr
Indoco Remedies Limited is incorporating a new wholly owned subsidiary, Warren Lifesciences Private Limited, for a cash investment of ₹0.01 Crore.
- Value
- ₹0.01 Cr
Other board meeting date announcements
All →Tapi Fruit Processing Board Meeting Date
Tapi Fruit Processing will hold a board meeting on November 3, 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. Trading window closes from October 1 to November 5, 2026.
Parag Milk Foods Board Meeting Date
Parag Milk Foods has notified BSE of a board meeting on 3 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. Trading window closure runs from 1 October to 5 November 2026.
Vedant Fashions Board Meeting Date
Vedant Fashions will hold a board meeting on 5 November 2026 to consider unaudited results for the quarter and half-year ended September 2026. The meeting is a prior intimation, so no results are approved yet.
Dangee Dums Board Meeting Date
Dangee Dums will hold a board meeting on 2 November 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. Trading window closure runs until 4 November 2026.
Relic Technologies Board Meeting Date
Relic Technologies intimated a board meeting on 2 Nov 2026 to consider unaudited standalone and consolidated Q2 results for the period ended 30 Sep 2026. The trading window closes from 1 Oct 2026 until 48 hours after the results are disseminated.
EPL Board Meeting Date
EPL will hold a board meeting on November 4, 2026 to consider September quarter results. Trading window re-opens 48 hours after results are declared.